Contrasting Theravance Biopharma (TBPH) & Azurrx Biopharm (AZRX)

Theravance Biopharma (NASDAQ: TBPH) and Azurrx Biopharm (NASDAQ:AZRX) are both small-cap pharmaceuticals – nec companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Earnings & Valuation

This table compares Theravance Biopharma and Azurrx Biopharm’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Theravance Biopharma $48.65 million 31.45 -$190.66 million ($5.16) -5.48
Azurrx Biopharm N/A N/A -$14.59 million N/A N/A

Azurrx Biopharm has higher revenue, but lower earnings than Theravance Biopharma.

Profitability

This table compares Theravance Biopharma and Azurrx Biopharm’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Theravance Biopharma -1,604.87% -99.43% -47.10%
Azurrx Biopharm N/A N/A -216.05%

Institutional & Insider Ownership

84.6% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 6.0% of Azurrx Biopharm shares are owned by institutional investors. 6.1% of Theravance Biopharma shares are owned by company insiders. Comparatively, 9.1% of Azurrx Biopharm shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Theravance Biopharma and Azurrx Biopharm, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Theravance Biopharma 1 0 5 0 2.67
Azurrx Biopharm 0 0 2 0 3.00

Theravance Biopharma presently has a consensus target price of $42.67, suggesting a potential upside of 50.87%. Azurrx Biopharm has a consensus target price of $7.50, suggesting a potential upside of 166.90%. Given Azurrx Biopharm’s stronger consensus rating and higher possible upside, analysts plainly believe Azurrx Biopharm is more favorable than Theravance Biopharma.

Summary

Azurrx Biopharm beats Theravance Biopharma on 6 of the 10 factors compared between the two stocks.

About Theravance Biopharma

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

About Azurrx Biopharm

AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).

Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply